Our mission is to safeguard the health of people worldwide. We are an Osaka University-spun-off healthcare startup in the healthcare/preventive medicine field, developing and providing the “Blood Vessel Beauty” scope—which observes capillary blood flow from the fingertip without blood sampling—along with the capillary image analysis software ‘CAS’ and the cloud-based evaluation system “CAS-Rating.” We research the relationship between capillary data and health/disease risks, aiming to implement new health indicators and preventive medical services in society.
Remohab is a medical device startup from Osaka University, working on the development of a remote cardiac rehabilitation system. As the first company in the Japan Bio design Program, its participation in Air Water Group is the first M&A exit case in Japan in the DTx (Digital Therapeutics) field. In 2024, its completed Japan’s first physician-initiated Phase III clinical trial for a remote cardiac rehabilitation system, and on June 23, 2025, its product “Remohab CR U” received approval from the Pharmaceuticals and Medical Devices Agency (PMDA). Remohab aims to launch the product in Japan first and promote its nationwide adoption with future global expansion in mind.
A startup has developed a painless, simple test using tears to detect cancer early and monitor for recurrence. Using cutting-edge technology originating from Kobe University, it enables highly sensitive detection of extracellular vesicles, allowing testing in everyday settings like homes or pharmacies.
Development and sales of solutions for preventing the worsening of diabetes complications.
A startup that synthesizes long, complex DNA using proprietary technology, enabling the flexible design of diverse gene combinations. It also provides comprehensive support from development to manufacturing processes for viral vectors and mRNA required for gene therapy.